Renalytix Share Discussion Threads

[tradertrev] 30/6/2023 15:03

As usual we sell out to the Yanks who make all the money. GLA

[hsdeo] 30/6/2023 14:55

continued sellers at 115

[mr roper] 30/6/2023 14:47

Last 3m Ave daily vol 52k
Today's vol 830k...

16x daily vol.

[waltzing] 30/6/2023 14:46

Toffee. Still up over 50% today volume or not

[wan] 30/6/2023 13:20

Pre-market volume in the US now over 3m and rising.

[wan] 30/6/2023 12:55

From the US market -

Renalytix jumps 38% after FDA nod for lead product
Jun. 30, 2023 7:24 AM

Renalytix Plc (NASDAQ:RNLX) added ~38% in the pre-market Friday after the company said it received the FDA's De Novo marketing authorization for its lead product, KidneyIntelX.dkd, designed to assess the risk of kidney function decline in adults with type 2 diabetes and chronic kidney disease.
Full story -

The US market does not open until 2:30pm UK time, and Nasdaq is showing pre-market volume of over 2m shares already. Given the FDA news was delivered quite late yesterday, it will be interesting to see where US investors place Renalytix shares.

[ny boy] 30/6/2023 10:19

The chart has completed the mountain formation, steps up the foothills have started

[mr roper] 30/6/2023 10:16

Welcome back, hpcg.

[hpcg] 30/6/2023 09:51

I bought back in this morning - it was the catalyst I was waiting for.

[mr roper] 30/6/2023 09:30

No reason it shouldn't be shifting back to the $5-10 range now. Fda is a big derisking point.

[faz] 30/6/2023 09:18

wan we'll wait and see. I was lucky to get out around the 600-800p mark. Ther is clear room for a company valued at $100m to be very successful if they manage their money now their product has been blessed by the FDA

[s34icknote] 30/6/2023 09:15

Follows Dnl and angle with fda approval . Fingers crossed they make some money before the next rights !

[wan] 30/6/2023 09:13

Faz...re staff...cue the recent EVERSANA partnership and indeed the potential from 'strategic' partnerships that Renalytix has apparently been working on for a long time, and that would have a measurable impact on KidneyIntelX usage.

[sos100] 30/6/2023 09:10

think it's nasdaq that leads the way here....afternoon will be interesting

[iceagefarmer] 30/6/2023 09:06

HOUSTON...WE HAVE LIFT OFF!

[faz] 30/6/2023 08:59

Yes wan, it may do well from here. But imho it needs a CFO to stand up to the CEO. Hospitals are funded either by the State and/or by insurance (that's a US and - increasingly - UK model); the cash comes in. Hospitals arent on NASDAQ; maybe if they were cash wastage would reduce. I'll be watching how the finances are managed over the next 12 months; for example recruiting 40 more staff tomorrow would show they've not learnt the lesson.

[wan] 30/6/2023 08:39

Faz...But others have failed to achieve what Renalytix has done 'ahead' of FDA approval. From one of my previous posts (2171) -


AdvaMed to CMS: “Patients Are Still Waiting—But We’re Encouraged Congress No Longer Wants to Wait”
Government & Legislative AffairsMay 10, 2023

“Increasingly, medical technology innovators are confronting a ‘valley of death’ where their technologies have received FDA authorization, but often no CMS or insurance coverage is in place to allow patients to gain access to them. Simply put, America’s seniors and patients across the country are all too often not getting timely access to critical medical technologies for many years, if ever.


So, Renalytix has done a lot of the ground work forming an effective bridge over the valley of death! Plus the deal with EVERSANA will extend and accelerate that progress. Hence the market should 'very much' appreciate FDA approval, which will hopefully come in June.
(END)

In short, Renalytix has put in place wide regional insurance coverage 'ahead' of FDA approval. Hence; "Renalytix believes FDA authorization will lead to increasing test adoption, informing clinical guidelines, expanding insurance coverage, and pursuing additional international regulatory approvals"

And I would add that given FDA approval is widely recognised beyond the US, I think it's natural to expect that additional international regulatory approvals will follow in due course.

[iceagefarmer] 30/6/2023 08:35

just bought a massive wedge here...will go ballistic when US opens

[nimbo1] 30/6/2023 08:30

Renx so far has been a diabolical investment - they have got timelines wrong (or perhaps right but lied to the market) on everything - including revenue projections, length of roll out and length to fda approval.

It is possible this marks a turning point for the business and it can 10x from here. But it could only ever be a tiny punt for me as its more likely they continue over promising and hosing money.

[babbler] 30/6/2023 08:22

They did a major raise recently at 90p

[wan] 30/6/2023 08:22

My reponse on Discord in the US regarding Renalytix being acquired.....Maybe, but an extension to the partnership with AstraZeneca would be preferable, and I don't see Renalytix being acquired before other catalytic events e.g. 'extension of the platform into "new indications and products", pharma and diagnostic partnerships etc. In short, the next stage of a disruptive and impactful journey is just getting underway.

[mr roper] 30/6/2023 08:21

Agree. Rnlx have a huge moat around the product based on real world test evidence published to date. Any competitor is probably 3 years behind minimum

[faz] 30/6/2023 08:20

It might cause a step change - why on earth would you spend over two years trying to get it - but I suspect a fund raise will now happen. BELL and POLX also heavily down since FDA approval - it's not a magic wand. If the CEO can show financial acumen - something he has singularly failed to do - over the next 12 months then this should develop nicely into a profitable company.